Rationale for combining a direct renin inhibitor with other renin - Angiotensin system blockers. Focus on aliskiren and combinations

Cardiovascular Drugs and Therapy

Volumn 25, Issue 1, 2011, Pages 87-97

  Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aliskiren; Angiotensin converting enzyme; Angiotensin receptor blockers; Combination therapy

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; PRORENIN; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; VALSARTAN;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; NONHUMAN; PATIENT COMPLIANCE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE; SYSTOLIC DYSFUNCTION; TREATMENT PLANNING;

AMIDES; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 79959945214     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6278-0     Document Type: Article

References (97)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-215.
2. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
4. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592-9. (Pubitemid 41725095)
5. Paul M, Poyan Mehr A, Kreutz R. Physiology of local reninangiotensin systems. Physiol Rev. 2006;86:747-803.
6. Li J, Doerffel Y, Hocher B, Unger T. Inflammation in the genesis of hypertension and its complications-the role of angiotensin II. Nephrol Dial Transplant. 2007;22:3107-9. (Pubitemid 350202578)
7. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164-71. (Pubitemid 36724261)
8. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-9. (Pubitemid 29323820)
9. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol. 2003;14:S246-9. (Pubitemid 36903934)
10. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985-91.
11. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-92. (Pubitemid 39031337)
12. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-82.
13. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-92. (Pubitemid 28429123)
14. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005;45:840-4. (Pubitemid 40628923)
15. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptorblocked rats. Hypertension. 2001;38:1272-7. (Pubitemid 34033401)
16. Padia SH, Howell NL, SiragyHM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537-44. (Pubitemid 43843872)
17. Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension. 2005;45:133-7. (Pubitemid 40066427)
18. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-6. (Pubitemid 46143011)
19. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-24. (Pubitemid 37464062)
20. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515-21. (Pubitemid 43843868)
21. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-43.
22. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-63. (Pubitemid 36842532)
23. Chai SY, Fernando R, Peck G, et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci. 2004;61:2728-37.
24. Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001;276:48623-6.
25. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-27. (Pubitemid 34596167)
26. Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension. 2005;46:1069-76. (Pubitemid 41533004)
27. Stankovic AR, Fisher ND, Hollenberg NK. Prorenin and angiotensin- dependent renal vasoconstriction in type 1 and type 2 diabetes. J Am Soc Nephrol. 2006;17:3293-9. (Pubitemid 44865272)
28. Deinum J, Ronn B, Mathiesen E, et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulindependent diabetes mellitus. Diabetologia. 1999;42:1006-10. (Pubitemid 29369610)
29. Siragy HM, Huang J. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Exp Physiol. 2008;93:709-14. (Pubitemid 351595048)
30. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-306.
31. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucoseinduced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H939-48. (Pubitemid 47254192)
32. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-13. (Pubitemid 43117745)
33. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Reninstimulated TGF-beta1 expression is regulated by a mitogenactivated protein kinase in mesangial cells. Kidney Int. 2007;72:45-52. (Pubitemid 47014443)
34. Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006;99:1355-66. (Pubitemid 44949671)
35. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension. 2008;51:1259-64. (Pubitemid 351555933)
36. Reudelhuber TL. Prorenin, renin, and their receptor. Moving targets. Hypertension 2010.
37. Muller DN, Hilgers KF, Mathews S, et al. Effects of human prorenin in rats transgenic for human angiotensinogen. Hypertension. 1999;33:312-7. (Pubitemid 29065677)
38. Veniant M, Menard J, Bruneval P, et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966-70. (Pubitemid 26376283)
39. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension. 2009;53:1062-9.
40. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1-8. (Pubitemid 27038966)
41. Verma S, Gupta M, Holmes D, et al. Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE study. Circulation. 2009;120:S453.
42. Bair TL, May HT, Prescott MF, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events. Presented at: American College of Cardiology Annual Meeting; March 29-31, 2009; Orlando, FL.
43. Parikh NI, Gona P, Larson MG, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J. 2007;28:2644-52. (Pubitemid 350071528)
44. Adiyaman A, Staessen JA. Renin turning full circle as cardiovascular risk factor. Eur Heart J. 2007;28:2557-8. (Pubitemid 350071514)
45. Laragh JH. Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173-7.
46. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens. 2010;23:929-30.
47. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316:1429-35.
48. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991; 325:293-302.
49. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
50. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342:821-8.
51. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62. (Pubitemid 23335891)
52. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med. 1996;334:939-45. (Pubitemid 26114159)
53. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-72. (Pubitemid 13204034)
54. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53-7. (Pubitemid 30042669)
55. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738-47. (Pubitemid 36750469)
56. Wei CC, Hase N, Inoue Y, et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-39.
57. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-45. (Pubitemid 30099477)
58. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40:1414-21. (Pubitemid 35192865)
59. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6. (Pubitemid 37093917)
60. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25:951-8. (Pubitemid 46573113)
61. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-479.
62. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49:S12-154.
63. Brown MJ. Aliskiren. Circulation. 2008;118:773-84.
64. Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1:264-77. (Pubitemid 47091546)
65. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45:880-6. (Pubitemid 40628932)
66. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71. (Pubitemid 37093916)
67. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. (Pubitemid 33126822)
68. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. (Pubitemid 37409706)
69. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59. (Pubitemid 351522739)
70. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2002;39:463-70. (Pubitemid 34117504)
71. Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: angiotensinreceptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693-704. (Pubitemid 39434842)
72. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14:181-8. (Pubitemid 351434594)
73. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007;167:1930-6. (Pubitemid 47606631)
74. Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHROND). Clin J Am Soc Nephrol. 2009;4:361-8.
75. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292-9. (Pubitemid 38295437)
76. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-8. (Pubitemid 351166266)
77. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-9. (Pubitemid 47069535)
78. McMurray JJ, Pitt B, Latini R, et al. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
79. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens. 2003;16:1066-73. (Pubitemid 37500805)
80. Berlowitz MS, Latif F, Hankins SR, et al. Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers. J Cardiovasc Pharmacol. 2001;37:692-6. (Pubitemid 32480437)
81. Diovan® (valsartan). Full Prescribing Information, Novartis Pharmacueticals, 2010.
82. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47:515-31. (Pubitemid 351969826)
83. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-63. (Pubitemid 46400330)
84. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589-99.
85. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130-6.
86. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-205.
87. Mezzano S, Droguett A, Burgos ME, et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl. 2003;86:S64-70. (Pubitemid 37159630)
88. Hodroj W, Legedz L, Foudi N, et al. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol. 2007;27:525-31.
89. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-33. (Pubitemid 39578845)
90. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-7.
91. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-46. (Pubitemid 351793017)
92. Yarows SA. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Rev Cardiovasc Ther. 2010;8:19-33.
93. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161-7. (Pubitemid 351159920)
94. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
95. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-83.
96. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663-71.
97. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24:1039-47. (Pubitemid 351579161)